Monoclonal Gammopathy of Undetermined Significance – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of monoclonal gammopathy of undetermined significance (MGUS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence in each country, as well as annualized case counts projected to the national population.

Clarivate epidemiology’s MGUS forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with MGUS per year?
• Of all people diagnosed with MGUS, how many in each country in the developed world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MGUS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases of MGUS for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following subpopulations:

• Diagnosed incident cases of MGUS.
• Diagnosed prevalent cases of MGUS.
• Diagnosed incident cases of MGUS progressed to multiple myeloma.

Note: Coverage may vary by country.